Company / PP&E (Net)
NEKTAR THERAPEUTICS PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.1M
FY2025
5-year range
$2.1M / $60.5M
FY2021-FY2025
Trend
-39.6%
vs FY2024
Sector context
#133 of 193
Health Care
What the data says
At $2M, NEKTAR THERAPEUTICS's pp&e (net) ranks #133 of 193 in the Health Care sector. PP&E (Net) has declined for 4 consecutive years, from $61M in FY2021 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -49.0%.
Declined from $19M to $2M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -60.1%
- 5-Year CAGR
- -49.0%
- 10-Year CAGR
- -
Sector benchmark
#133 of 193 in Health CareTop 69% of 193This company $2.1M Sector average $777.6M
▼
-99.7% below sector average
Key checks
Key Insights
- NEKTAR THERAPEUTICS's pp&e (net) has declined for 4 consecutive years.
- 5-year CAGR of -49.0%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 39.6% year-over-year.
- Ranks #133 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1M | -39.6% |
| FY2024 | $3.4M | -81.9% |
| FY2023 | $18.9M | -41.9% |
| FY2022 | $32.5M | -46.4% |
| FY2021 | $60.5M | +1.4% |
| FY2020 | $59.7M | -8.2% |
| FY2019 | $65.0M | +33.1% |
| FY2018 | $48.9M | +2.9% |
| FY2017 | $47.5M | -27.6% |
| FY2016 | $65.6M | -8.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026